Clinical Trials · NCT05861830
Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES)
- Phase
- Phase 3
- Recruitment status
- Unknown
- Sponsor
- Peking Union Medical College Hospital
- Enrollment
- 80
- Start date
- May 2023
- Locations
- 1 site, China
- Primary endpoint
- Investigator-assessed PFS